celgosivir

Celgosivir is an oral small molecule prodrug of castanospermine, a natural product derived from the seeds of Castanospermum australe. It acts as a potent inhibitor of alpha-glucosidase I (and to some extent II), host enzymes involved in the glycosylation and maturation of viral envelope glycoproteins. By inhibiting these enzymes, celgosivir disrupts the proper folding and assembly of enveloped viruses, thereby blocking their replication and release. Celgosivir has demonstrated broad-spectrum antiviral activity in vitro against hepatitis C virus (HCV) and all four serotypes of dengue virus (DENV). It is rapidly converted to castanospermine in vivo after oral administration. Clinical trials have shown that while celgosivir is generally safe and well tolerated, it does not significantly reduce viral load or fever burden as monotherapy for dengue fever but may have synergistic effects when combined with standard HCV therapies such as pegylated interferon alfa-2b plus ribavirin[1][5][6][7].

Other names

celgosivir hydrochloride